Thank you, healthcare workers, for all you do. Your determination to help others is truly inspiring. Please stay safe.
Decision Making in Advanced NSCLC: The Community Physician Perspective on Immunotherapy
E-Publication E-Publication

Decision Making in Advanced NSCLC: The Community Physician Perspective on Immunotherapy


Released:
4/2/2020
Expires:
4/1/2021

Maximum Credits:

1.0
By clicking "Continue," you confirm that you have reviewed the CME information.

E-Publication E-Publication
By clicking "Continue," you confirm that you have reviewed the CME information.
Released:
4/2/2020

Expires:
4/1/2021

Maximum Credits:
1.0
E-Publication E-Publication
By clicking "Continue," you confirm that you have reviewed the CME information.

Released:
4/2/2020
Expires:
4/1/2021


Maximum Credits:
1.0


Overview: This accredited CME activity reviews the clinical evidence around immunotherapy for the treatment of advanced non–small cell lung cancer (NSCLC), including immune checkpoint inhibitor (ICI) monotherapy, chemoimmunotherapy, dual ICI therapy, and quadruple drug regimens, as well as the current role of predictive biomarkers in treatment selection. Special considerations regarding ICI usage in patients with driver mutations or a high risk of immune-related adverse events (irAEs) are also discussed. Each section includes a short video clip of a conversation between Drs. David Spigel and Ioana Bonta that provides insights into clinical decision making in this rapidly evolving treatment landscape.

NOTE: This activity was developed before the US FDA approval of the nivolumab plus ipilimumab combination in metastatic NSCLC in May 2020. Refer to the respective package inserts for more information.

CME Information:

Faculty
Ioana Bonta, MD 
Medical Oncologist 
Georgia Cancer Specialists 
Atlanta, GA 

David Spigel, MD
Chief Scientific Officer
Director, Lung Cancer Research Program
Sarah Cannon
Nashville, TN
 
Activity Planners
Lori Pender, PharmD, MPH, BCOP
Manager, Educational Strategy and Content
Med-IQ
Baltimore, MD

Laura Rafferty, ELS
Managing Editor
Med-IQ
Baltimore, MD

Samantha Gordon
CME Specialist
Med-IQ
Baltimore, MD

Kathryn Schaefer, MSN, RN, CPHRM
Senior Manager, Accreditation and Compliance
Med-IQ
East Lansing, MI 

Writer
Stephanie Wenick, MPhil
Wenick Communications, LLC
Chevy Chase, MD
  
Learning Objectives
Upon completion, participants should be able to:

  • Describe the pros and cons of using PD-L1 expression and TMB as predictive biomarkers in advanced NSCLC
  • Apply evidence from clinical trials, including molecular test results, when selecting treatment for patients with advanced NSCLC across lines of therapy
  • Discuss methods to proactively identify and manage irAEs in at-risk patients with NSCLC

Target Audience
This activity is intended for medical oncologists, nurse practitioners, physician assistants, and other healthcare providers who treat and/or manage patients with lung cancer. 
 
Statement of Need
The management of advanced NSCLC is becoming increasingly complex as a result of the rapid expansion of treatment options, nuances regarding biomarker-based clinical decision making, and the potential for irAEs with immunotherapy-based regimens. To optimize outcomes for these patients, it is critical that healthcare providers stay current in a rapidly evolving clinical landscape that requires them to order and interpret molecular tests, personalize treatment selection across lines of therapy, and anticipate and safely manage irAEs for their patients with advanced NSCLC. 

Providership Statement
Provided by Med-IQ. 
 
Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
 
Med-IQ designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners, physician assistants, and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available. 
 
Medium/Method of Participation
This CME activity consists of a 1.0-credit online publication. To receive credit, read the introductory CME material, read the publication, and complete the post-survey, evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly. 

Initial Release Date: April 2, 2020
Expiration Date: April 1, 2021
Estimated Time to Complete This Activity: 1 hour

Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.

Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation. 
 
Ioana Bonta, MD 
Consulting fees/advisory boards: Novartis Pharmaceuticals Corporation

David Spigel, MD, has indicated no real or apparent conflicts. 
 
The writer, peer reviewers, and activity planners have no financial relationships to disclose.
 
Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
 
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.
 
Contact Information        
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email info@med-iq.com.

System Requirements

Desktop

Mobile

  • Operating system - Med-IQ supports the current operating system, plus two prior releases:
    • Android (eg, Samsung Galaxy)
    • Apple (eg, iPhone/iPad)
  • Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
    • Android (Chrome)
    • Apple (Safari)

Applications & Software

For technical assistance, please refer to our Support Manual.

Disclaimer
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy notice, please visit: www.med-iq.com/privacy-statement/.

Acknowledgment of Commercial Support
This activity is supported by an educational grant from Bristol-Myers Squibb. 
 
Copyright
© 2020 Med-IQ, Inc.

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

Need help? If you need to speak with a member of our team, please call (toll-free) 866 858 7434 or email info@med-iq.com. For technical assistance, please refer to our support manual.

We recently updated our Privacy Notice and Terms of Use.